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Background. Fecalmicrobiota transplantation (FMT)has been shown tobe effective in recurrentClostridiumdifficile (CD) infection,
with resolution in 80% to 90%of patients.However, immunosuppressed patientswere often excluded fromFMT trials, so safety and
efficacy in this population are unknown. Methods. We searched MEDLINE and EMBASE for English language articles published
on FMT for treatment of CD infection in immunocompromised patients (including patients on immunosuppressant medications,
patients with human immunodeficiency virus (HIV), inherited or primary immunodeficiency syndromes, cancer undergoing
chemotherapy, or organ transplant, including-bone marrow transplant) of all ages. We excluded inflammatory bowel disease
patients that were not on immunosuppressant medications. Resolution and adverse event rates (including secondary infection,
rehospitalization, and death) were calculated. Results. Forty-four studies were included, none of which were randomized designs.
A total of 303 immunocompromised patients were studied. Mean patient age was 57.3 years. Immunosuppressant medication use
was the reason for the immunocompromised state in the majority (77.2%), and 19.2% had greater than one immunocompromising
condition. Seventy-six percent were given FMT via colonoscopy. Of the 234 patients with reported follow-up outcomes, 207/234
(87%) reported resolution after first treatment, with 93% noting success after multiple treatments. There were 2 reported deaths,
2 colectomies, 5 treatment-related infections, and 10 subsequent hospitalizations. Conclusion. We found evidence that supports
the use of FMT for treatment of CD infection in immunocompromised patients, with similar rates of serious adverse events to
immunocompetent patients.
1. Introduction
Clostridium difficile (CD) infection is the leading cause of
healthcare-associated diarrheal illness in the United States,
affecting nearly 500,000 patients annually [1, 2]. Both inci-
dence and severity of CD infection have increased over
the past two decades, and CD infection is now responsible
for 29,000 deaths/year within 30 days of diagnosis [1].
Immunocompromised patients, including those receiving
immunosuppressant medications or patients with human
immunodeficiency virus (HIV) and transplants, seem to be
at increased risk of hospitalization and recurrence of CD
infection as the immune system is an important defense for
both protection and recovery from infection [3–6].
Antibiotics have long been the mainstay of treatment for
CD infection. However, 25% of patients suffer recurrence of
CD infection within 60 days of antibiotic therapy [7, 8]. FMT
has emerged as an effective alternative for the relapsed and
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refractory CD infection patients with reported success rates
of 80-90% in clinical trials [9, 10]. Due to safety concerns
related to introducing bacterial therapy in immunocompro-
mised patients, those with immunocompromised states have
been excluded from most trials, and guidelines currently
recommend caution in these patient populations due to the
absence of safety and efficacy data [11, 12].
The aim of our study is to conduct a systematic review of
the existing literature to collate the evidence for efficacy and
safety of FMT in immunocompromised population.
2. Methods
We searched PubMed, EMBASE, and Google Scholar for
English language articles published on FMT for treatment of
CD infection from inception through May 2017.
These databases were searched using the search terms
under 2 broad search themes of “Clostridium difficile” and
“fecal microbiota transplantation” and were combined using
a Boolean operator AND (see supplementary file 1). For the
term “Clostridium difficile”, we used a combination of MeSH
entry term words Clostridium difficile and C. difficile. For the
MeSH term “fecal microbiota transplantation”, we used syn-
onyms for fecal microbiota transplantation, intestinal micro-
biota transfer, donor feces infusion, and stool transplant. We
made the decision not to include the term “immunocompro-
mised” due to concerns that our search would not capture the
patients broadly enough. We instead reviewed all individual
articles for descriptions of treated patients who matched our
definition of immunocompromised.
We defined a patient as immunocompromised if that pa-
tient was receiving immunosuppressive agents (including but
not limited to mTOR inhibitors, calcineurin inhibitors, anti-
TNF agents, other biologic agents, high dose steroids > 20
mg/day or ≥ 1 mg/kg for > 14 days), patients with human
immunodeficiency virus (HIV) infection (regardless of CD4
count), acquired immune deficiency syndrome (AIDS),
inherited or primary immunodeficiency syndromes, hemato-
logicmalignancy or solid tumor (activewith treatment in past
3 months or in remission for less than 5 years), solid organ
transplant, and/or bone marrow transplant. We excluded
inflammatory bowel disease (IBD) patients that were not
receiving immunosuppressantmedications.We also excluded
patient with chronic medical conditions such as chronic liver
disease, chronic kidney disease, and autoimmune conditions
not on immunosuppressant. We included patients of all age
groups.
Our outcomes of interest were clinical resolution of
diarrhea, bacteriologic resolution, treatment failure, adverse
events, and mortality. Clinical or bacteriologic resolution
was defined as absence of diarrhea or need for further
CDI treatment after FMT within the study or follow-up
period clinically or with C. difficile toxin testing, respectively.
Treatment failure was defined as nonresponse or recurrence
of diarrhea with or without positive C. difficile toxin. We
defined post-FMT death as any death within 30 days of FMT.
We reviewed all study types with original data published
in English language. The reference lists of included articles
and chosen articles were manually hand-searched for addi-
tional articles. Our eligibility criteria for inclusion were as
follows: (1) studies of any type on human subjects with a
full published manuscript whomet at least one of our defini-
tions for immunocompromised, (2) received fecal transplant
via any method for a laboratory-confirmed, symptomatic CD
infection, and (3) any of the outcomes of interestwas reported
in the manuscript. We included patients who received FMT
in inpatient, outpatient, or home setting. We excluded studies
that evaluated FMT for non-CD illness. We excluded con-
ference abstracts to avoid duplication of our study popula-
tion with a subsequent full publication. We excluded stud-
ies that did not report on any of our outcomes or had mixed
population of immunocompromised and immunocompetent
patients that did not report outcomes of immunocompro-
mised population separately.
Three reviewers (YF, SV, and OS) independently screened
titles and abstracts and excluded irrelevant studies. Full
manuscript review was conducted by three investigators (YF,
SV, and OS) to determine inclusion eligibility. Disagreement
on inclusion was adjudicated by a third investigator (AD).
Data extractionwas performed by 3 investigators (GS, AJ, and
SV) and reviewed for accuracy by a third investigator (OS).
We extracted data on patient’s characteristics includ-
ing age, gender, number of CD infections prior to FMT,
interventions prior to FMT, time from index CD infection
diagnosis to FMT,method of diagnosis of indexCD infection,
and reasons for immune compromise. We collected study
characteristics including study type, location, clinical setting,
and duration of study including length of follow-up period.
We also extracted FMT treatment data, including delivery
method (upper GI infusion, capsule ingestion, colonoscopic
infusion, or enema), number of treatments, whether fresh or
frozen stool was administered, treatment dose infused, stool
donor relationship (related or unrelated), pretransplant bowel
preparation, and pretransplant use of antibiotics. Outcome
data collected included resolution of clinical symptoms,
treatment failure after single FMT, all-cause mortality within
30 days, number of relapses, and need for additional FMT
prior to resolution. We also categorized adverse events
including colectomy, CD/FMT-related deaths, new hospital-
izations, life-threatening events, need for surgery, infection
complications, IBD flares, and time from infection to adverse
event. A CD/FMT-related adverse event was defined as any
complication or new event occurring within 30 days of first
FMT. Duplicate patient entries were identified and removed.
Authors were contacted for clarification on data where
necessary.
We assessed study quality using questions from the NIH
quality assessment tool for case series studies. We conducted
quality assessment only on studies with at least five patients
in original study population (Supplementary file 2) [57].
We did pooled studies and calculated resolution and
adverse event rateswith 95% confidence interval using STATA
version 13 (College Station, TX).We set statistical significance
at p ≤ 0.05. Some studies reported adverse events but had
missing data for efficacy. Given the importance of adverse
event outcomes in immunocompromised patients, we con-
ducted separate efficacy and safety analyses.
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1318 Articles identiﬁed through
PubMed, EMBASE, hand search
Articles aer duplicates removed
(n =998)
Articles aer title review
(n =513)
Articles excluded
(n =485)
Articles aer abstract review
(n = 147)
Articles aer full text review
(n = 44)
Articles excluded (n = 103)
No Immunocompromised: 85
Reviews, Systematic reviews, or
meta-analyses: 10
No separate data for IC: 10
No full text: 8
Articles excluded (n = 368)
Reviews, Systematic reviews, expert
opinion or meta-analyses: 109
No outcome of interest: 80
No Immunocompromised: 92
Abstract and Posters: 60
Did not assess FMT: 21
FMT for non CDI: 24
No human participant: 2
Figure 1: Flowchart for study selection.
There were no randomized controlled trials and study
heterogeneity between the nonrandomized trials precluded
performing a meta-analysis on our included studies.
3. Results
We identified 44 studies whichmet inclusion criteria describ-
ing 303 patients (Figure 1) [13–56]. Forty-three were single
cases or case series and one was a retrospective cohort study,
and no randomized designswere identified (Table 1). Of those
studies reporting gender, 62% were females and 38% were
males. The mean age was 57.3 years (range: 2-88 years). The
most common reason for the immunocompromised state
was use of immunosuppressant medication (77.2%). Other
reasons for being immunocompromised included solid organ
transplant (18.2%), active malignancy including lymphoma
or leukemia (16.2%), hematopoietic stem cell transplant
(2.5%), and HIV/AIDS (2.1%). There was more than one
immunocompromising condition in 19.9% of patients.
Patient averaged about 2.5 episodes of CD prior to first
FMT. Most patients (73.7%) had received other treatments
for CD infection, mainly antibiotics, before FMT, with
many (48.6%) receiving 2 or more CD infection treatments
prior to FMT. Treatments other than antibiotics prior to
FMT included probiotics, intravenous immunoglobulin, and
surgery. For patients that received antibiotics prior to FMT,
antibiotics were stopped on average about 1.5 days (range: 0-
3, SD: 0.55 days) prior to FMT procedure.
Colonoscopy was the route of delivery of FMT in 76%
of patients, while 21% had stool transplanted via ingestion
of capsules or other upper gastrointestinal route (nasal tubes
or endoscopy). Retention enema was performed in 7.6 %
of patients. Most patients (95%) received fresh stool, while
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5% utilized commercially prepared products. Among those
reporting source of stool, a related donor was employed in
75% of patients.
A total of 234 patients had data on outcome and were
included in the efficacy analysis. Of these, 206 (87.7%) had
clinical resolution of CD infection after first FMT treatment,
while 93% had resolution after 2 or more FMT attempts.
Comparing rate of resolution by delivery method, colono-
scopy delivered FMT had an 84% success rate, while upper
gastrointestinal delivery (via endoscopy, capsule, and naso-
gastric or nasojejunal tubes) resulted in 92% success rate (p =
0.202). In terms of number of immunocompromising condi-
tions, patients with one condition had a success rate of 93%,
while those with two or more immunocompromising condi-
tions were resolved 78% of the time (Odds ratio (OR) 0.24,
95% CI: 0.11- 0.51, p<0.0001).
All 303 patients were included in the safety analysis.
There were 2 reported deaths. Both deaths were in patients
with solid organ transplants. One patient died 13 days after
successful FMT, with death due to progressive pneumonia,
while the second patient died 1 day after FMT following aspi-
ration pneumonitis during sedation for colonoscopy. Other
reported adverse events include 2 colectomies, 5 episodes
of bacteremia or infection, 10 subsequent hospitalizations, 7
otherwise unspecified life-threatening complications, and 7
flares of inflammatory bowel disease. Twenty-eight patients
had other complications including abdominal pain, irritable
bowel syndrome, nausea, fever, and diverticulitis post-FMT
procedure. Mean time to adverse event was 26.6 days (range:
0-56, SD: 34.3 days) from FMT (Table 2).
Twenty of the included 43 case reports/studies had at least
5 patients in the original study population. Only 10 studies
showed adequate reporting in all of six essential domains of
study quality (study objective, case definition, outcome mea-
sure definition, FMT procedure, adequacy of follow-up, and
donor characteristics), with others missing 1 to 3 of these
elements (Supplementary file 2).
4. Discussion
Our review identified an 88% success rate after a single FMT
and 93% after multiple FMTs in our immunocompromised
population, which parallels the 80-90% success rates reported
in the general population [9, 10]. Patients with a single
immunocompromising factor had a higher rate of treatment
success when compared to patients with multiple immuno-
compromising factors (p<0.001). In comparison, a retrospec-
tive series by Kelly et al. looking at 80 immunocompromised
patients with CD infection treated with FMT reported a
78% cure rate following a single FMT and 89% cure rate
with multiple FMT [28]. Of these 80 patients, 38 met our
inclusion criteria and were included in our analyses. A recent
systematic review and meta-analysis by Ianiro et al. found
a similar cure rate of 93% after multiple FMT with a 76%
cure rate after a single FMT [58]. While Ianiro et al. excluded
case reports and case series with less than 10 patients who
received FMT for CDI with a minimum of 8 weeks follow-
up, our study focused on only immunocompromised patients
regardless of the study size given our already limited study
population.
Safety concernswere the rationale for excluding immuno-
compromised patients from clinical trials and expression of
caution in guidelines for FMT. We identified just 2 deaths
among out 303 patients with 30 days of FMT. Both deaths
were reported in a retrospective review by Kelly et al. but we
could not directly ascertain whether those deaths were
directly related to FMT, to the CD infection or the patient’s
underlying immunocompromised states. Other deaths in
our included studies were either not related to FMT (post-
colectomy complications) or occurred beyond 30 days after
FMT [23, 37]. Of those reporting rehospitalization following
FMT, 8.3% reported this. While fecal transplant has been
associated with reactivation of existing immune-mediated
disorders or new disorders such as immune thrombocy-
topenia, rheumatoid arthritis in immunocompetent patients
following treatment, this side effect was not identified in our
study [59]. It is possible that the underlying immunosuppres-
sed states of our study population may have suppressed any
adverse immunologic responses observed in immunocompe-
tent patients.
Our study has the following strengths. It addresses a
very specific population with CD infection that has a higher
incidence of CD infection with higher risk of recurrence and
would ideally benefit from FMT. In addition, we included
only patients who met a standard, predetermined definition
of immunosuppression. However, our study has some limi-
tations. We reviewed case reports and series, as there were
no RCTs that were identified for inclusion. Inclusion of case
reports with possibility of publication bias towards positive
results might account for the high success rate after a single
FMT. Missing data on demographics, method of stool trans-
plantation, volume and amount of stool, and relationships of
donor and recipients were common in our review and were
also noted in a similar review by Bafeta et al. [60].One clinical
trial had immunocompromised patients that met inclusion
criteria but had a mixed population of patients that included
immunocompetent patients and did not provide separate
data on the included immunocompromised population and
therefore could not be included in our study [61]. Our efforts
at contacting authors to provide data on immunocompro-
mised patients were unsuccessful. In the absence of clinical
trials, overall studies were too heterogeneous precluding a
meta-analysis.
5. Conclusion
In conclusion, FMT in immunocompromised appears to have
comparable efficacy and safety data to those on patients with
intact immunity. However, due to heterogeneity of immuno-
suppression subtype, no solid conclusion can be made about
any single specific immunocompromised states or a combi-
nation regarding response to FMT. Further randomized trials
including these patient populations would be appropriate.
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Table 2: Adverse events (AE) in immunocompromised patients with recurrent CD infection treated with FMT.
Author, Year Patients with events (N) Type of AE
Friedman-Moraco, 2014
[22] 1 Life threatening event: ischemic stroke
Hirsch, 2015 [27] 1 New Hospitalization
1 Life threatening event
1 Abdominal pain
Kelly, 2014 [29] 1 Colectomy
1 Death
1 Death
5 New Hospitalization
1 Life threatening event
3 Infection: pneumonia, Influenza, Pertussis
4 IBD flare
11 Others:
Hip pain
Nausea
Bloating
Fever
Diarrhea
Abdominal pain
Catheter infection
Self-limited diarrhea
Minor mucosal tear during colonoscopy
Laszlo, 2016 [32] 1 Others: Mild abdominal pain
Lee, 2014 [34] 1 New Hospitalization/Life threatening event
Mandalia, 2016 [36] 3 IBD flare
1 Diverticulitis
Mittal, 2015 [38] 1 New Hospitalization
Pierog, 2014 [42] 1 Life-threatening event/New
Hospitalizations/Surgery
Quera, 2013 [44] 1 Life threatening event
Infection: Pan-sensitive E. coli
Russell, 2014 [48] 1 Colectomy/New Hospitalization/Life threateningevents/Surgery
Silverman, 2010 [50] 3 IBS
Webb, 2016 [53] 5 Abdominal pain
Weingarden, 2013 [54] 1 Colectomy
AE= adverse event; IBS= irritable bowel syndrome.
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